Academic Journals Database
Disseminating quality controlled scientific knowledge

Golimumab and certolizumab: The two new anti-tumor necrosis factor kids on the block

Author(s): Mittal Mohit | Raychaudhuri Siba

Journal: Indian Journal of Dermatology, Venereology and Leprology
ISSN 0378-6323

Volume: 76;
Issue: 6;
Start page: 602;
Date: 2010;
Original page

Keywords: Anti-tumor necrosis factor agents | Certolizumab | Golimumab

Anti-tumor necrosis factor (anti-TNF) agents have revolutionized treatment of psoriasis and many other inflammatory diseases of autoimmune origin. They have considerable advantages over the existing immunomodulators. Anti-TNF agents are designed to target a very specific component of the immune-mediated inflammatory cascades. Thus, they have lower risks of systemic side-effects. In a brief period of 10 years, a growing number of biological therapies are entering the clinical arena while many more biologicals remain on the horizon. With time, the long-term side-effects and efficacies of these individual agents will become clearer and help to determine which ones are the most suitable for long-term care. Golimumab (a human monoclonal anti-TNF-α antibody) and Certolizumab (a PEGylated Fab fragment of humanized monoclonal TNF-α antibody) are the two latest additions to the anti-TNF regimen. Here, we are providing a brief description about these two drugs and their uses.
Why do you need a reservation system?      Affiliate Program